Prodrug Bioavailability
Prodrug Bioavailability is the fraction and rate at which the active drug moiety, following enzymatic or chemical conversion from its pharmacologically inactive prodrug form, becomes available at the systemic circulation and target sites of action within the body.
76
Publications
2.5K
Citations
371
Authors
95
Institutions
Publications per year
2017–2026
11
76
Michael R. Harnden, Richard L. Jarvest, Malcolm R. Boyd et al. · Journal of Medicinal Chemistry · 1989 · 100 citations
1–5 of 76
371
6
h-index
6
h-index
5
h-index
5
h-index
5
h-index
1–5 of 371
95
University of Michigan
Ann Arbor, United States
9 h-index
36 publications
1.8K citations
Schools of Visual Arts, The Royal Danish Academy of Fine Arts
Copenhagen, Denmark
8 h-index
18 publications
444 citations

Christian-Albrechts-Universität zu Kiel
Kiel, Germany
6 h-index
26 publications
1.4K citations

University of Eastern Finland
Joensuu, Finland
4 h-index
21 publications
664 citations
AstraZeneca (Sweden)
Södertälje, Sweden
3 h-index
7 publications
195 citations

Johns Hopkins University
Baltimore, United States
3 h-index
30 publications
1.1K citations
University of Florida
Gainesville, United States
2 h-index
3 publications
125 citations

Rabin Medical Center
Petah Tikva, Israel
2 h-index
4 publications
100 citations
1–8 of 95
13 publications · 450 citations
12
h-index
8 publications · 480 citations
8
h-index
7 publications · 181 citations
7
h-index
4 publications · 76 citations
4
h-index
3 publications · 77 citations
3
h-index
1–5